

# Michael J Cork

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9301736/publications.pdf>

Version: 2024-02-01

126  
papers

7,946  
citations

81900

39  
h-index

51608

86  
g-index

142  
all docs

142  
docs citations

142  
times ranked

5921  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adverse effects of topical glucocorticosteroids. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, 1-15.	1.2	893
2	Epidermal Barrier Dysfunction in Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 2009, 129, 1892-1908.	0.7	612
3	Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 818-823.	2.9	594
4	New perspectives on epidermal barrier dysfunction in atopic dermatitis: Gene-environment interactions. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 118, 3-21.	2.9	465
5	Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial. <i>British Journal of Dermatology</i> , 2018, 178, 1083-1101.	1.5	380
6	Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)*. <i>British Journal of Dermatology</i> , 2021, 184, 437-449.	1.5	289
7	Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2020, 396, 255-266.	13.7	273
8	Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. <i>British Journal of Dermatology</i> , 2000, 142, 52-58.	1.5	245
9	Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse. <i>British Journal of Dermatology</i> , 2003, 149, 582-589.	1.5	227
10	ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2717-2744.	2.4	220
11	Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. <i>Lancet</i> , The, 2020, 395, 962-972.	13.7	178
12	Severity of Alopecia Areata Is Associated with a Polymorphism in the Interleukin-1 Receptor Antagonist Gene. <i>Journal of Investigative Dermatology</i> , 1994, 103, 387-390.	0.7	172
13	When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 623-633.	1.2	170
14	Topical preparations for the treatment of psoriasis: a systematic review. <i>British Journal of Dermatology</i> , 2002, 146, 351-364.	1.5	158
15	Genetic Association Between an AACC Insertion in the 3'UTR of the Stratum Corneum Chymotryptic Enzyme Gene and Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 2004, 123, 62-66.	0.7	148
16	Effect of Olive and Sunflower Seed Oil on the Adult Skin Barrier: Implications for Neonatal Skin Care. <i>Pediatric Dermatology</i> , 2013, 30, 42-50.	0.9	145
17	Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase II open-label trial and subsequent phase III open-label extension. <i>British Journal of Dermatology</i> , 2020, 182, 85-96.	1.5	111
18	The importance of skin barrier function. <i>Journal of Dermatological Treatment</i> , 1997, 8, S7-S13.	2.2	102

#	ARTICLE	IF	CITATIONS
19	Bathing and cleansing in newborns from day 1 to first year of life: recommendations from a European round table meeting. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 751-759.	2.4	101
20	European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e241-e242.	2.4	99
21	Recommendations from a European Roundtable Meeting on Best Practice Healthy Infant Skin Care. <i>Pediatric Dermatology</i> , 2016, 33, 311-321.	0.9	98
22	Topical treatments for chronic plaque psoriasis. <i>The Cochrane Library</i> , 2013, , CD005028.	2.8	90
23	Role of the Autoimmune Regulator ( <i>AIRE</i> ) gene in alopecia areata: Strong association of a potentially functional <i>AIRE</i> polymorphism with alopecia universalis. <i>Tissue Antigens</i> , 2002, 60, 489-495.	1.0	74
24	Skin barrier breakdown: a renaissance in emollient therapy. <i>British Journal of Nursing</i> , 2009, 18, 872-877.	0.7	74
25	The effect of aqueous cream BP on the skin barrier in volunteers with a previous history of atopic dermatitis. <i>British Journal of Dermatology</i> , 2011, 165, 329-334.	1.5	73
26	Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. <i>Journal of Dermatological Treatment</i> , 2020, 31, 606-614.	2.2	72
27	Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants. <i>Pediatric Allergy and Immunology</i> , 2015, 26, 306-315.	2.6	71
28	Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis. <i>JID Innovations</i> , 2022, 2, 100131.	2.4	66
29	The effect of tacrolimus compared with betamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis. <i>British Journal of Dermatology</i> , 2014, 170, 914-921.	1.5	63
30	Effect on skin hydration of using baby wipes to clean the napkin area of newborn babies: assessor-blinded randomised controlled equivalence trial. <i>BMC Pediatrics</i> , 2012, 12, 59.	1.7	61
31	The Effect of an Emollient Containing Urea, Ceramide NP, and Lactate on Skin Barrier Structure and Function in Older People with Dry Skin. <i>Skin Pharmacology and Physiology</i> , 2016, 29, 135-147.	2.5	58
32	The development of a preference-based measure of health in children with atopic dermatitis. <i>British Journal of Dermatology</i> , 2005, 153, 372-377.	1.5	57
33	Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (The BEEP trial): protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 343.	1.6	56
34	Structure and polymorphism of the human gene for the interferon-induced p78 protein (MX1): evidence of association with alopecia areata in the Down syndrome region. <i>Human Genetics</i> , 2000, 106, 639-645.	3.8	54
35	The autoimmune regulator gene ( <i>AIRE</i> ) is strongly associated with vitiligo. <i>British Journal of Dermatology</i> , 2008, 159, ???-???	1.5	54
36	The Effect of Water Hardness on Surfactant Deposition after Washing and Subsequent Skin Irritation in Atopic Dermatitis Patients and Healthy Control Subjects. <i>Journal of Investigative Dermatology</i> , 2018, 138, 68-77.	0.7	54

#	ARTICLE	IF	CITATIONS
37	Topical treatments for chronic plaque psoriasis: An abridged Cochrane Systematic Review —. Journal of the American Academy of Dermatology, 2013, 69, 799-807.	1.2	51
38	Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy — international eczema council survey and opinion. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1224-1231.	2.4	50
39	Randomized, Controlled Trial Evaluating a Baby Wash Product on Skin Barrier Function in Healthy, Term Neonates. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 2013, 42, 203-214.	0.5	46
40	Dupilumab provides favourable long-term safety and efficacy in children aged 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. British Journal of Dermatology, 2021, 184, 857-870.	1.5	45
41	Topical treatments for chronic plaque psoriasis of the scalp: a systematic review. British Journal of Dermatology, 2013, 169, 519-527.	1.5	44
42	Topical treatments for chronic plaque psoriasis. , 2009, , CD005028.		43
43	Atopic dermatitis epidemiology and unmet need in the United Kingdom. Journal of Dermatological Treatment, 2020, 31, 801-809.	2.2	43
44	A functional mechanistic study of the effect of emollients on the structure and function of the skin barrier. British Journal of Dermatology, 2016, 175, 1011-1019.	1.5	39
45	pH in Atopic Dermatitis. Current Problems in Dermatology, 2018, 54, 95-107.	0.7	39
46	Skincare interventions in infants for preventing eczema and food allergy: A cochrane systematic review and individual participant data meta-analysis. Clinical and Experimental Allergy, 2021, 51, 402-418.	2.9	38
47	Infant skin-cleansing product versus water: A pilot randomized, assessor-blinded controlled trial. BMC Pediatrics, 2011, 11, 35.	1.7	37
48	Skin care interventions in infants for preventing eczema and food allergy. The Cochrane Library, 2021, 2021, CD013534.	2.8	37
49	Diaper dermatitis prevalence and severity: Global perspective on the impact of caregiver behavior. Pediatric Dermatology, 2020, 37, 130-136.	0.9	34
50	Alterations in the desquamation-related proteolytic cleavage of corneodesmosin and other corneodesmosomal proteins in psoriatic lesional epidermis. British Journal of Dermatology, 2008, 159, 77-85.	1.5	32
51	Improved emollient use reduces atopic eczema symptoms and is cost neutral in infants: before-and-after evaluation of a multifaceted educational support programme. BMC Dermatology, 2013, 13, 7.	2.1	31
52	Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). American Journal of Clinical Dermatology, 2022, 23, 365-383.	6.7	30
53	European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e308-e311.	2.4	27
54	Treatment of Grover's disease with calcipotriol (Dovonex®). British Journal of Dermatology, 1995, 132, 832-833.	1.5	26

#	ARTICLE	IF	CITATIONS
55	Use of oil for baby skincare: A survey of UK maternity and neonatal units. <i>British Journal of Midwifery</i> , 2011, 19, 354-362.	0.4	25
56	Sub-clinical assessment of atopic dermatitis severity using angiographic optical coherence tomography. <i>Biomedical Optics Express</i> , 2018, 9, 2001.	2.9	24
57	Enhancement of stratum corneum lipid structure improves skin barrier function and protects against irritation in adults with dry, eczema-prone skin*. <i>British Journal of Dermatology</i> , 2022, 186, 875-886.	1.5	24
58	Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis—A pooled analysis of trial data. <i>Pediatric Dermatology</i> , 2022, 39, 187-196.	0.9	23
59	The Challenges and Realities of Diaper Area Cleansing for Parents. <i>JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing</i> , 2012, 41, E13-E25.	0.5	22
60	Vitamin D and antimicrobial peptide levels in patients with atopic dermatitis and atopic dermatitis complicated by eczema herpeticum: A pilot study. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1715-1719.e4.	2.9	22
61	European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e839-e842.	2.4	22
62	Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 422-433.	2.4	22
63	Vehicles for atopic dermatitis therapies: more than just a placebo. <i>Journal of Dermatological Treatment</i> , 2022, 33, 685-698.	2.2	21
64	Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA <sup>2</sup> LEN position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1736-1750.	5.7	21
65	Clinical and Cytological Effects of Pimecrolimus Cream 1% after Resolution of Active Atopic Dermatitis Lesions by Topical Corticosteroids: A Randomized Controlled Trial. <i>Dermatology</i> , 2011, 222, 36-48.	2.1	20
66	Association analysis of IL1A and IL1B variants in alopecia areata. <i>Heredity</i> , 2001, 87, 215-219.	2.6	19
67	Aqueous cream damages the skin barrier. <i>British Journal of Dermatology</i> , 2011, 164, 1179-1180.	1.5	18
68	Development of stratum corneum chymotrypsin-like protease activity and natural moisturizing factors from birth to 4 weeks of age compared with adults. <i>British Journal of Dermatology</i> , 2016, 175, 713-720.	1.5	18
69	Computational design of treatment strategies for proactive therapy on atopic dermatitis using optimal control theory. <i>Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences</i> , 2017, 375, 20160285.	3.4	17
70	An Investigation of the Skin Barrier Restoring Effects of a Cream and Lotion Containing Ceramides in a Multi-vesicular Emulsion in People with Dry, Eczema-Prone, Skin: The RESTORE Study Phase 1. <i>Dermatology and Therapy</i> , 2020, 10, 1031-1041.	3.0	17
71	Novel interleukin-1 receptor antagonist exon polymorphisms and their use in allele-specific mRNA assessment. <i>Human Genetics</i> , 1996, 97, 723-726.	3.8	17
72	British Society for Paediatric Dermatology. <i>British Journal of Dermatology</i> , 2009, 161, 115-127.	1.5	16

#	ARTICLE	IF	CITATIONS
73	A single-blind comparison of topical erythromycin/zinc lotion and oral minocycline in the treatment of acne vulgaris. <i>Journal of Dermatological Treatment</i> , 1993, 4, 119-122.	2.2	15
74	The role of in atopic eczema: treatment strategies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 1996, 7, S31-S37.	2.4	15
75	Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey-based position statement. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 807-815.	2.4	15
76	The effect of water hardness on atopic eczema, skin barrier function: A systematic review, meta-analysis. <i>Clinical and Experimental Allergy</i> , 2021, 51, 430-451.	2.9	15
77	Laboratory Safety of Dupilumab in Patients Aged 6–11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial. <i>Paediatric Drugs</i> , 2021, 23, 515-527.	3.1	15
78	Different types of emollient cream exhibit diverse physiological effects on the skin barrier in adults with atopic dermatitis. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 1154-1164.	1.3	15
79	Infant Skin Barrier, Structure, and Enzymatic Activity Differ from Those of Adult in an East Asian Cohort. <i>BioMed Research International</i> , 2018, 2018, 1-8.	1.9	11
80	Randomized controlled pilot trial with ion-exchange water softeners to prevent eczema (SOFTER) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.9	10
81	Cytokine dermatosis: reactivation of eczema during interleukin-2 infusion. <i>British Journal of Dermatology</i> , 1997, 136, 644-645.	1.5	9
82	Hygiene and emollient interventions for maintaining skin integrity in older people in hospital and residential care settings. <i>The Cochrane Library</i> , 2014, , .	2.8	9
83	Protocol for an outcome assessor-blinded pilot randomised controlled trial of an ion-exchange water softener for the prevention of atopic eczema in neonates, with an embedded mechanistic study: the Softened Water for Eczema Prevention (SOFTER) trial. <i>BMJ Open</i> , 2019, 9, e027168.	1.9	8
84	Skincare interventions in infants for preventing eczema and food allergy. <i>The Cochrane Library</i> , 2020, , .	2.8	7
85	Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials. <i>Dermatitis</i> , 2021, 32, S81-S91.	1.6	7
86	Predisposition to sensitive skin and atopic eczema. <i>Community Practitioner</i> , 2005, 78, 440-2.	0.1	7
87	Topical preparations for the treatment of psoriasis: a systematic review. <i>British Journal of Dermatology</i> , 2000, 142, 351-364.	1.5	6
88	Comparison of the Simple Patient-Centric Atopic Dermatitis Scoring System PEST with SCORAD in Young Children Using a Ceramide Dominant Therapeutic Moisturizer. <i>Dermatology and Therapy</i> , 2017, 7, 383-393.	3.0	6
89	ä,€é;1á...³ãŽ dupilumab æ²»ç—æ¹;ç—1é²á°á¹´æ,£è€...çš,,ç”ç©¶. <i>British Journal of Dermatology</i> , 2020, 182, e47-447.		6
90	A Predictive Self-Organizing Multicellular Computational Model of Infant Skin Permeability to Topically Applied Substances. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2049-2055.e1.	0.7	6

#	ARTICLE	IF	CITATIONS
91	The effects of pimecrolimus on the innate immune response in atopic dermatitis. <i>British Journal of Dermatology</i> , 2013, 168, 235-236.	1.5	5
92	Eumovate™ (clobetasone butyrate 0.05%) cream: a review of clinical efficacy and safety. <i>Journal of Dermatological Treatment</i> , 2003, 14, 71-85.	2.2	4
93	Patient education about topical treatments. <i>British Journal of Dermatology</i> , 2011, 165, 1159-1160.	1.5	4
94	Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis and other atopic comorbidities. <i>Allergy and Asthma Proceedings</i> , 2021, 42, 425-431.	2.2	4
95	Dupilumab reduces absenteeism in patients with moderate to severe atopic dermatitis: Pooled results from the LIBERTY AD SOLO clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1499-1501.	1.2	3
96	Imaging striae distensae: a comparison between PS-OCT and digital dermoscopy. <i>Biomedical Optics Express</i> , 2021, 12, 3296.	2.9	3
97	Gene-environment interactions in atopic dermatitis. <i>Drug Discovery Today Disease Mechanisms</i> , 2008, 5, e11-e31.	0.8	2
98	Topical oils for the prevention or treatment of dry skin in term infants. <i>The Cochrane Library</i> , 2014, , .	2.8	2
99	Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial. <i>British Journal of Dermatology</i> , 2018, 178, e366-e366.	1.5	2
100	Epidermal barrier dysfunction in atopic dermatitis. <i>Series in Dermatological Treatment</i> , 2008, , 35-58.	0.1	2
101	P479 Dupilumab improves patient-reported outcomes in atopic dermatitis patients inadequately controlled, intolerant, or inadvisable for cyclosporine-A. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 119, S94-S95.	1.0	1
102	605 Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis. <i>Journal of Investigative Dermatology</i> , 2019, 139, S104.	0.7	1
103	Specifically Targeting Interleukin-13 with Tralokinumab Improved Sleep in Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials in Patients with Atopic Dermatitis. <i>SKIN the Journal of Cutaneous Medicine</i> , 2021, 5, s9.	0.3	1
104	Skin Barrier Dysfunction in Atopic Dermatitis. <i>Basic and Clinical Dermatology</i> , 2009, , 211-240.	0.1	1
105	P193 DUPILUMAB DECREASES TOTAL AND ALLERGEN-SPECIFIC IGE IN ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS (AD). <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 127, S54-S55.	1.0	1
106	Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and Older. <i>Dermatology and Therapy</i> , 2021, 11, 1643-1656.	3.0	1
107	Cytokine gene activation across the advancing edge of psoriatic plaques. <i>Journal of Dermatological Science</i> , 1993, 6, 2.	1.9	0
108	Cytokine gene polymorphisms in inflammatory dermatoses. <i>Journal of Dermatological Science</i> , 1993, 6, 18.	1.9	0

#	ARTICLE	IF	CITATIONS
109	Optical coherence tomography demonstrates differential epidermal thinning of human forearm volar skin after 2 weeks application of a topical corticosteroid vs a non-steroidal anti-inflammatory alternative. , 2013, , .		0
110	The British Skin Foundation: 20 years of supporting dermatology research. British Journal of Dermatology, 2017, 177, 608-609.	1.5	0
111	æœâCE¹é²â•æš—ç»“â•ã¼/éšæ€šâ±€éƒ“çš®è“ç±»â•ºé††æ²»ç—â•¹çž•â€ç‘Aâº”ç”â,â,â.....â†æ^—â,è€â—æ^—è€...âœ”â€»â†,âšâ,â»è®©â€		
112	P302 EFFICACY OF CRISABOROLE IN PATIENTS WITH MILD-TO-MODERATE ATOPIC DERMATITIS WITH AND WITHOUT FOOD ALLERGIES. Annals of Allergy, Asthma and Immunology, 2020, 125, S40-S41.	1.0	0
113	15413 Dupilumab improves signs and symptoms in adult and adolescent patients with erythrodermic atopic dermatitis: A pooled subgroup analysis. Journal of the American Academy of Dermatology, 2020, 83, AB39.	1.2	0
114	16818 An investigation of the skin barrier restoring effects of a cream containing ceramides in a multivesicular emulsion in people with dry, eczema-prone, skin: The RESTORE study phase 2. Journal of the American Academy of Dermatology, 2020, 83, AB71.	1.2	0
115	455 Dupilumab monotherapy improves signs, symptoms and quality of life in adult and adolescent patients with erythrodermic atopic dermatitis. Journal of Investigative Dermatology, 2020, 140, S60.	0.7	0
116	A study of dupilumab in the treatment of adolescents with eczema. British Journal of Dermatology, 2020, 182, e30-e30.	1.5	0
117	Patient-Reported Outcomes (PROs) With Abrocitinib Treatment in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN Study. Journal of Allergy and Clinical Immunology, 2021, 147, AB156.	2.9	0
118	Efficacy and Safety of Crisaborole in Patients With Mild-to-Moderate Atopic Dermatitis With Comorbid Allergic Rhinitis or Asthma. Journal of Allergy and Clinical Immunology, 2021, 147, AB28.	2.9	0
119	484 Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs and symptoms and quality of life (QoL) in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial. Journal of Investigative Dermatology, 2021, 141, S84.	0.7	0
120	27394 Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs, symptoms, and quality of life in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial. Journal of the American Academy of Dermatology, 2021, 85, AB141.	1.2	0
121	26880 Long-term efficacy and safety data for dupilumab in a phase 3, open-label extension trial (LIBERTY) Tj ETQq1 1 0.784314 rgBT (AD). Journal of the American Academy of Dermatology, 2021, 85, AB120.	1.2	0
122	26875 52-week laboratory safety findings from an open-label extension (OLE) study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE). Journal of the American Academy of Dermatology, 2021, 85, AB120.	1.2	0
123	27350 Dupilumab improves Eczema Area and Severity Index regional scores across all anatomical regions in children aged 6â€“11 years with severe atopic dermatitis (AD). Journal of the American Academy of Dermatology, 2021, 85, AB136.	1.2	0
124	26304 Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis with and without comorbid allergies or asthma. Journal of the American Academy of Dermatology, 2021, 85, AB97.	1.2	0
125	Response to: Letter to the Editor Regarding â€œAn Investigation of the Skin Barrier Restoring Effects of a Cream and Lotion Containing Ceramides in a Multi-Vesicular Emulsion in People with Dry, Eczema-Prone, Skin: The RESTORE Study Phase 1â€• Dermatology and Therapy, 2021, 11, 2249-2252.	3.0	0
126	161â€...52-Week Laboratory Safety Findings From an Open-Label Extension Study of Dupilumab in Adolescent Patients With Atopic Dermatitis (LIBERTY AD PED-OLE). , 2021, , .		0